GALT News & Events

Galectin Therapeutics announced the oral and poster presentations of new analyses from its global NAVIGATE trial of belapectin at the European Association for the Study of the Liver Congress 2026, or EASL. "The analyses presented at EASL 2026 provide important new insight into how belapectin may modify disease progression in patients with advanced MASH cirrhosis and portal hypertension," said Khurram Jamil, chief medical officer of Galectin Therapeutics. "The oral presentation demonstrates a mechanistic link between modulation of fibrogenesis balance, as reflected by the Pro-C3/CTX-III ratio, and reduced varices development in high-risk patients (i.e. ELF scores greater than or equal to11.3, a threshold consistent with cirrhosis). These findings are consistent with the biologic effect we would expect to observe if belapectin is meaningfully impacting the underlying fibrotic disease process. The poster analyses further support that these biologic effects translate into clinically meaningful reductions in portal hypertension risk, including improvements in liver stiffness and Baveno risk category. Taken together, the consistency of findings across the dataset strengthens the overall evidence supporting belapectin's disease-modifying potential."

Galectin Therapeutics announced the publication of results from its NAVIGATE Phase 2b clinical trial evaluating belapectin in patients with MASH cirrhosis and portal hypertension in AASLD flagship journal Hepatology. "These results further strengthen the clinical and mechanistic profile of belapectin in MASH cirrhosis and portal hypertension," said Khurram Jamil, chief medical officer of Galectin Therapeutics. "The consistency across clinical outcomes and noninvasive biomarkers, including signals of reduced risk of clinically significant portal hypertension and variceal development, reinforces our confidence in belapectin's potential to modify disease progression. We believe these data meaningfully support continued advancement of our program, while positioning belapectin as a differentiated therapeutic candidate in MASH cirrhosis with portal hypertension-a market with significant unmet need and limited treatment options."

Galectin Therapeutics files $200M mixed securities shelf

Galectin Therapeutics has appointed Henry Brem, M.D., as an independent director to its Board of Directors. Dr. Brem is an internationally recognized neurosurgeon-scientist and leader in translational medicine. He serves as the Henry Brem Professor of Neurosurgery at Johns Hopkins University and previously served as Director of the Department of Neurosurgery and Neurosurgeon-in-Chief at The Johns Hopkins Medical Institutions. He is also Co-Director of the Brain Cancer Program at the Sidney Kimmel Comprehensive Cancer Center.